TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma  by Anido, Judit et al.
Cancer Cell
ArticleTGF-b Receptor Inhibitors Target
the CD44high/Id1high Glioma-Initiating Cell
Population in Human Glioblastoma
Judit Anido,1 Andrea Sa´ez-Borderı´as,1 Alba Gonza`lez-Junca`,1 Laura Rodo´n,1 Gerard Folch,1 Maria A. Carmona,1
Rosa M. Prieto-Sa´nchez,1 Ignasi Barba,2 Elena Martı´nez-Sa´ez,3 Ludmila Prudkin,1 Isabel Cuartas,1 Carolina Ravento´s,1
Francisco Martı´nez-Ricarte,4 M. Antonia Poca,4 David Garcı´a-Dorado,2 Michael M. Lahn,5 Jonathan M. Yingling,5
Jordi Rodo´n,1 Juan Sahuquillo,4,6 Jose´ Baselga,1,6 and Joan Seoane1,6,7,*
1Vall d’Hebron Institute of Oncology, Barcelona 08035, Spain
2Cardiovascular Program
3Pathology Program
4Department of Neurosurgery, Vall d’Hebron University Hospital Research Institute, Barcelona 08035, Spain
5Eli Lilly and Co., Indianapolis, IN 46225, USA
6Autonomous University of Barcelona, Cerdanyola del Valle`s 08193, Spain
7Institucio´ Catalana de Recerca i Estudis Avanc¸ats (ICREA), Barcelona 08010, Spain
*Correspondence: jseoane@vhio.net
DOI 10.1016/j.ccr.2010.10.023SUMMARYGlioma-initiating cells (GICs), also called glioma stem cells, are responsible for tumor initiation, relapse, and
therapeutic resistance. Here, we show that TGF-b inhibitors, currently under clinical development, target the
GIC compartment in human glioblastoma (GBM) patients. Using patient-derived specimens, we have deter-
mined the gene responses to TGF-b inhibition, which include inhibitors of DNA-binding protein (Id)-1 and -3
transcription factors. We have identified a cell population enriched for GICs that expresses high levels of
CD44 and Id1 and tend to be located in a perivascular niche. The inhibition of the TGF-b pathway decreases
the CD44high/Id1high GIC population through the repression of Id1 and Id3 levels, therefore inhibiting the
capacity of cells to initiate tumors. High CD44 and Id1 levels confer poor prognosis in GBM patients.INTRODUCTION
Work over the last several years has shown that the TGF-b
signaling pathway has an important role in cancer (Massague,
2008), and this has prompted the development of anticancer
strategies based on inhibition of this pathway (Seoane, 2008;
Yingling et al., 2004). However, due to the complexity of the
TGF-b signaling pathway, it is crucial to understand how
TGF-b inhibition affects tumor biology in order to assess and
improve the therapeutic potential and clinical testing of anti-
TGF-b compounds.
TGF-b is a cytokine that signals through a heterodimeric
receptor complex formed by the type I (TbRI) and the type IISignificance
GBM is one of the most aggressive and recalcitrant tumors and
therapeutic approaches have been described to target GICs.
have observed that the inhibition of the TGF-b pathway targ
CD44 and Id1, which is enriched for GICs. The depletion of the C
tumor initiation and recurrence. Our work shows that Id1 and
combined CD44 and Id1 expression confers poor prognosis in
the clinical development of TGFb inhibitors as compounds tar
Can(TbRII) receptors. Upon ligand binding, the receptor complex
phosphorylates Smad transcription factors, which then shuttle
into the nucleus to regulate transcription (Massague et al.,
2005; Schmierer andHill, 2007). Functionally, the TGF-b pathway
is relevant in embryonic development and tissue homeostasis,
and exhibits a pleiotropic response determined by the cellular
context and state (Massague, 2008).
The TGF-b pathway acts as an oncogenic factor in advanced
tumors, including high-grade gliomas (Massague, 2008). Glioma
is the most common tumor of the brain, and its most aggressive
form, grade IV glioma, also called glioblastoma (GBM), is one
of the deadliest cancers with a median survival of around
14months (Stupp et al., 2005). In glioma, elevated TGF-b activityGICs are responsible for therapeutic failures. Still, not many
Through the study of patient-derived tumor specimens, we
ets a cell population characterized by high expression of
D44high/Id1high GIC population by TGF-b inhibitors prevents
Id3 are therapeutic targets against GICs and GBM, and that
patients. Furthermore, our results have clear implications on
geting GICs.
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TbRI Inhibitors Target CD44high/Id1high GICsconfers poor prognosis in patients (Bruna et al., 2007), and
shows a diverse oncogenic response that includes the induction
of angiogenesis, immunosuppression, cell invasion, and cell
proliferation (Bruna et al., 2007; Rich, 2003). In addition, TGF-b
can increase the self-renewal capacity of glioma-initiating cells
(GICs) through the induction of LIF or Sox2 (Ikushima et al.,
2009; Penuelas et al., 2009).
In tumors, cancer-initiating cells (CICs), including GICs, are
a cellular subpopulation that have characteristics of normal
stem cells, exhibit sustained self-renewal, and can generate
secondary tumors that reproduce the characteristics and cellular
diversity of the original tumor. CICs are considered to be respon-
sible for tumor initiation, propagation, recurrence, and chemo-
and radioresistance (Bao et al., 2006; Dick, 2008; Gupta et al.,
2009a; Visvader and Lindeman, 2008; Zhou et al., 2009). All
these characteristics indicate that CICs are critical therapeutic
targets, and that the understanding of the biology of CICs is
crucial to improving anticancer treatments. A number of cell
surfacemarkers, including CD133 andCD44, have proved useful
for the isolation of subsets of cells enriched for CICs in different
tumor types (Visvader and Lindeman, 2008). In glioma, CD133
has been frequently used to identify GICs, although some
gliomas contain CD133-negative GICs (Bao et al., 2006; Beier
et al., 2007; Galli et al., 2004; Singh et al., 2004). In contrast,
the CD44 compartment has not been extensively studied in
glioma. In breast cancer, a link between TGF-b and the CD44high
population has been described. TGF-b has been shown to
increase the CD44high cell population enriched for CICs through
the induction of an epithelial-mesenchymal transition (EMT)
(Gupta et al., 2009b; Mani et al., 2008).
Inhibitors of DNA-binding proteins (Ids) are transcription
factors that antagonize the DNA-binding capacity of basic
helix-loop-helix factors (Perk et al., 2005). Ids regulate cell cycle
and cell differentiation, and have an important role in the control
of stem cell self-renewal (Perk et al., 2005; Ying et al., 2003). Very
recently, Id1 has been shown to be expressed in B1 type adult
neural stem cells, having an important role in the regulation of
the self-renewal capacity of these cells (Nam and Benezra,
2009). In cancer, Id1 is found upregulated in several tumors
(Perk et al., 2006), and has been described to be involved in
metastasis (Gupta et al., 2007). TGF-b family members regulate
the expression of Id1. In normal epithelial cells, TGF-b represses
and BMP induces Id1 transcription (Massague, 2008). However,
in endothelial cells and some tumor cells, TGF-b is able to induce
Id1 expression (Goumans et al., 2002; Padua et al., 2008).
In this study, we investigated themolecular mechanisms of the
antitumor effect of the inhibition of the TGF-b pathway in GBM.
RESULTS
The TbRI Inhibitor Gene Responses in GBM Include
Id1 and Id3
With the purpose of understanding the effect of the inhibition of
the TGF-b pathway in GBM, we decided to identify the gene
responses to the TbRI inhibition in patient-derived primary
cultures of tumor cells (PCTCs). In order to inhibit the TbRI, we
used a highly selective compound that acts as an ATP compet-
itor, LY2109761, a derivative of which is now in a phase I-II
clinical trial in our hospital (Vall d’Hebron University Hospital,656 Cancer Cell 18, 655–668, December 14, 2010 ª2010 Elsevier IncBarcelona, Spain). We obtained cells from surgically resected
human GBM samples and generated 11 PCTCs from 11 different
patients. Shortly after setting up the cultures, cells were treated
with the TbRI inhibitor for 3 hr and the RNA was collected. We
used the lowest concentration of inhibitor required to prevent
the phosphorylation of Smad2 (2 mM) (see Figure S1A available
online).We performed a transcriptomic analysis and determined
the transcripts that were modulated by the treatment with the
TbRI inhibitor (Figure 1A). A signature of TGF-b inhibition was ob-
tained with six transcripts that were regulated by the TbRI inhib-
itor with a fold change over 1.4 or below 0.6, and a p < 0.001. We
validated the gene responses that were the most significantly
regulated: ID3, ID1, Smad7, and RhoB (Figure 1B). All four genes
were modulated by the TbRI inhibitor in almost all PCTCs. In
particular, ID3 and ID1 were downregulated in all PCTCs with
the exception of PCTC2. Interestingly, PCTC2 was generated
from the only GBM of our set that presented cysts (Figure S1B).
Next, we assessed whether Id1 and Id3 could be targets of the
TbRI inhibitor in vivo by use of a preclinical model based on the
orthotopical inoculation of patient-derived GICs in immunocom-
promisedmice.We generated neurosphere cultures enriched for
GICs from two GBM patient samples and inoculated them in the
brain of NOD-SCID mice. As we and others have described
(Penuelas et al., 2009; Visvader and Lindeman, 2008), GICs
generated tumors with similar characteristics to the original
tumor from the patient (Figure S1C). Mice inoculated with
patient-derived neurospheres were treated orally with the TbRI
inhibitor twice a day for 30 days and tumor progression was
monitored by magnetic resonance imaging (MRI). Mice treated
with the TbRI inhibitor generated smaller tumors and had a longer
survival rate than mice treated with the vehicle (Figures 1C and
1D; Figure S1D). We determined the levels of Id1 in the tumors
and found that the TbRI inhibitor-treated tumors exhibited lower
levels of Id1 than control tumors (Figure 1E). In order to exclude
the Id1-positive endothelial cells, we performed costaining of Id1
and the endothelial cell marker CD31 (Figure 1E). We also per-
formed Id3 analysis and found that the difference of Id3 levels
between mice treated or untreated with the TbRI inhibitor was
not statistically significant (Figure S1E and data not shown).
The effect of the TbRI inhibitor on ID1 was confirmed by tumor
microdissection and posterior analysis of mRNA by qRT-PCR
(Figure 1F). Globally, our results showed that Id1 is a target of
the TbRI inhibitor in human GBM.
Ids have been shown to be involved in stem cell biology (Nam
and Benezra, 2009; Ying et al., 2003), and we therefore hypoth-
esized that Id1 downregulation by the TbRI inhibitor could be
relevant for the maintenance of GICs. We first determined the
levels of Id1 and Id3 in PCTCs and GBM neurospheres, and
found that GBM neurospheres expressed higher levels of Id1
and Id3 than did PCTCs (Figure S2). We then assessed the effect
of the TbRI inhibitor on GBM neurospheres. We dissociated neu-
rospheres into single cells, plated them at low density, treated
them with the TbRI inhibitor for 7 days, and then counted the
newly formed neurospheres. Treatment of GBM neurospheres
with the TbRI inhibitor decreased the levels of p-Smad2 (Fig-
ure 2A) and the number of neurosphere-forming cells (Figure 2B).
Alternatively, neurospheres were treated for 7 days with the TbRI
inhibitor, then dissociated and replated in the absence of treat-
ment for another 7 days, and the newly formed neurospheres.
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Figure 1. Id1 Is a Target of the TbRI Inhibitor
in PCTCs and in a Patient-Derived Mouse
Model for Glioma
(A) The genes were regulated by the treatment with
2 mM TbRI inhibitor for 3 hr in 11 human glioma
PCTCs with a fold change over 1.4 or below 0.6
and a p < 0.001.
(B) ID3, ID1, Smad7, and RhoB transcript levels
were determined by qRT-PCR analysis. GAPDH
RNA levels were used as an internal normalization
control. *p < 0.05; **p < 0.001. Data are presented
as means ± SD.
(C and D) Cells from GBM1 and GBM2 neuro-
spheres were inoculated in the brain of immuno-
compromised mice. Twenty days after surgery,
mice were orally treated twice a day with
100 mg/kg of TbRI inhibitor for 30 days. (C) Tumor
area was quantified. (D) Images from the entire
mouse brains were obtained by MRI (arrowheads
indicate tumors).
(E) Immunohistochemistry for Id1 (upper panel)
and double immunofluorescence for Id1 and
CD31 (middle panel) were performed in tumors
generated by GBM neurospheres. For immunoflu-
orescence, nuclei were counterstained with
Hoechst. Scale bar, 100 mm. Representative
images are shown and percentage of Id1-positive
cells was calculated (lower panel). Data are pre-
sented as means ± SD.
(F) Cells from GBM1 neurospheres were inocu-
lated in the brain of immunocompromised mice.
Forty days after surgery, mice were orally treated
twice a day with 100 mg/kg of TbRI inhibitor for
10 days. Subsequently, 10 mm slides from
mouse brains were stained with H&E and tumors
were localized and microdissected. ID1 tran-
script levels were determined by qRT-PCR
(n = 4 for vehicle; n = 3 for TbRI inhibitor). Data
are presented as means ± SD. See also Fig-
ure S1.
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was maintained upon serial plating in the absence of treatment,
showing that the TbRI inhibitor decreases the neurosphere self-
renewal capacity (Figure 2C). The effect of the TbRI inhibitor on
GBM neurospheres from four different patients coincided with
a decrease in the mRNA levels of ID1 and ID3 (Figure 2D).
As expected, TGF-b induced Id1 expression in human GBM
neurospheres. TGF-b-mediated Id1 induction was prevented by
the treatment with two unrelated TbRI inhibitors, LY2109761
and SB431542 (Figures 3A and 3B; Figure S3). We then decided
to discern the mechanism through which TGF-b regulates Id1
expression. To study the transcriptional regulation of Id1 by
TGF-b, we used a reporter construct containing the 1046/+86
promoter regionof thehuman ID1gene.TGF-band theTbRI inhib-
itor were able to regulate the ID1 reporter construct, indicating
that TGF-b regulated ID1 at the level of transcription (Figure 3C).
Moreover, we were able to map the TGF-b-responsive element
to the 1046/863 promoter region, since the 863/+86 regionCandid not respond to TGF-b and the 1046/863 promoter region
wassufficient tobe regulatedbyTGF-band theTbRI inhibitor (Fig-
ure 3C). The1046/863 promoter region is the same region that
has been described to mediate the induction of ID1 transcription
by BMP and the repression of ID1 transcription by TGF-b in
epithelial cells (Kang et al., 2003; Lopez-Rovira et al., 2002). To
assess whether the transcriptional regulation of ID1 was Smad
dependent, we knocked down Smad4 by RNA interference.
TGF-b-mediated induction of Id1 was reduced when Smad4
was knocked down, indicating that Id1 is regulated by the
TGF-b-Smad pathway (Figure 3D). Moreover, chromatin
immunoprecipitation (ChIP) assays showed that Smad4 bound
the TGF-b-responsive element in the ID1 promoter after TGF-b
treatment (Figure 3E). These results indicate that TGF-b regulates
ID1 transcription throughamechanismsimilar to that described in
epithelial cells. However, while TGF-b induces ID1 transcription in
GBM neurospheres, TGF-b represses ID1 transcription in epithe-
lial cells (e.g., a human keratinocyte cell line, HaCaT) (Figure 3F).cer Cell 18, 655–668, December 14, 2010 ª2010 Elsevier Inc. 657
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Figure 2. Id1 and Id3 Expression and
Neurosphere Formation Are Regulated by
the TbRI Inhibitor in Patient-Derived
Neurospheres
(A) Cells from the indicated GBM neurospheres
were incubated with 2 mM TbRI inhibitor for 8 hr
and the levels of p-Smad2 and total Smad2 were
determined by immunoblotting.
(B) Equal numbers of dissociated cells from the
indicated GBM neurospheres were seeded at low
density and incubated with 2 mM TbRI inhibitor
for 7 days, after which the number of neurospheres
was determined. Data are presented as means ±
SD.
(C) Cells from the indicated GBM neurospheres
were incubated in the presence of 2 mMTbRI inhib-
itor for 7 days. Subsequently, cells were dissoci-
ated, counted, and equal numbers of dissociated
cells were replated at low density without treat-
ment. After 7 days, the percentage of neuro-
sphere-forming cells was determined. Data are
presented as means ± SD.
(D) Cells from the indicated GBM neurospheres
were incubated with 2 mM TbRI inhibitor for 8 hr
and the levels of ID1 and ID3 expression were
determined by qRT-PCR. *p < 0.05; **p < 0.001.
Data are presented as means ± SD. See also Fig-
ure S2.
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lial cells and some tumor cell lines (Goumans et al., 2002; Padua
et al., 2008).
We decided to address the mechanism of the differential Id1
response to TGF-b in GBM neurospheres and epithelial cells. A
previous report (Kang et al., 2003) showed that Id1 transcription
is repressed by TGF-b in epithelial cells through an ATF3-Smad
complex that binds to the ID1 promoter. The authors showed
that ATF3 acted as a transcriptional repressor, andwas recruited
to the ID1 promoter by the Smad complex. Interestingly, they
showed that ATF3 was induced by TGF-b and TNF-a. We found
that GBM neurospheres did not express ATF3, and, moreover,
that TGF-b did not induce ATF3 (Figure 3F). However, when
GBM neurospheres were treated with TNF-a, ATF3 was induced
as described by Kang et al. (2003), and TGF-b lost its ability to
induce Id1 (Figure 3G). Overall, our results show that the dual
response of Id1 to TGF-b depends on the activity of the TNF-a
pathway. Hence, the crosstalk between the TGF-b and the
TNF-a pathways through a downstream mediator (most likely
ATF3) dictates the transcriptional regulation of Id1 in GBM
neurospheres.
The TbRI Inhibitor Targets a CD44high/Id1high Cell
Compartment Enriched for GICs
We determined the expression of Id1 in neurospheres by immu-
nofluorescence and observed that the expression pattern was658 Cancer Cell 18, 655–668, December 14, 2010 ª2010 Elsevier Inc.heterogeneous, with some cells express-
ing high levels of nuclear Id1 (Figure 4A;
Figure S4A). In order to assess in which
cell compartment Id1 was expressed,
we analyzed by coimmunofluorescencethe expression of well-described markers of GICs (CD44,
SSEA-1, and CD133) and Id1 in four different patient-derived
neurospheres. High expression of Id1 colocalized with high
expression of CD44, but not with SSEA-1 or CD133 (CD133
was not expressed in GBM1 neurospheres) (Figure 4A; Fig-
ure S4B). We quantified the expression of CD44 and Id1, and
observed a direct correlation between CD44 and Id1 levels (Fig-
ure 4A). Interestingly, in GBM specimens (Figure S4C) and GBM
neurospheres (Figure 4B), we could distinguish two discrete
populations expressing different levels of CD44. The CD44high
andCD44 low subpopulations of neurospheres from four different
patients were sorted by flow cytometry, and Id1 expression
levels were determined. Id1 and Id3 were detected at much
higher levels in the CD44high than in the CD44low compartment
(Figures 4B and 4C). Interestingly, this was not the case,
however, for Id2, another member of the Id family of transcription
factors (Figure 4B).
We addressed whether the CD44high cell population in
glioma was enriched for GICs. First, we observed that, when
we induced differentiation of patient-derived neurospheres
through treatment with serum, the CD44high compartment dis-
appeared (Figure 5A). Next, we sorted the CD44high and
CD44low cells and serial plated them at low density. CD44high
cells generated more neurospheres than the CD44low compart-
ment (Figure 5B), indicating that the CD44high cells had higher
self-renewal capacity. The small number of neurospheres
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Figure 3. TGF-b Pathway Regulates Id1 Expression through an Activated Smad Complex
(A) Cells from GBM neurospheres were treated with 2 mMTbRI inhibitor for 8 hr with 100 pM TGF-b1 added, or not, during the last 3 hr, as indicated. The levels of
Id1, p-Smad2, Smad2, and tubulin were determined by immunoblotting.
(B) Cells fromGBM4 neurospheres were treated with 100 pM TGF-b1 during 3 hr and/or 2 mMTbRI inhibitors SB431542 and LY2109761 for 8 hr, or left untreated,
and the levels of Id1, p-Smad2, Smad2, and tubulin were determined by immunoblotting.
(C) GBM4 neurospheres were transfected with the indicated constructs and treated with 100 pM TGF-b1 and/or 2 mMTbRI inhibitor during 36 hr. Luciferase anal-
ysis was performed. *p < 0.05; **p < 0.001 compared with their respective controls. Data are presented as means ± SD.
(D) GBM4 neurospheres were transfected with the indicated siRNA. After 48 hr, cells were treated with 100 pM TGF-b during 3 hr, or left untreated. Levels of Id1,
Smad4, and tubulin were determined by immunoblotting.
(E) Cells from GBM4 neurospheres were treated with 100 pM TGF-b for 45 min, after which cells were lysed and ChIP performed with the indicated antibodies.
PCR analysis was performed with specific primers for the ID1 and GAPDH promoters.
(F) GBM4 neurospheres andHaCaT cells were incubated in the presence or absence of TGF-b (100 pM) for 3 hr. Nuclear protein extractionwas performed and the
levels of Id1, ATF3, and lamin A/C were determined by immunobloting.
(G) GBM4 neurospheres were treated with TNF-a (10 ng/ml) or TGF-b (100 pM) for 4 and 3 hr, respectively. Nuclear protein extraction was performed and the
levels of Id1, ATF3, and lamin A/C were determined by immunoblotting. See also Figure S3.
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(Figure S5A).
We then analyzed the tumor-initiating capacity of the CD44high
and the CD44low compartments. We sorted tumor cells based on
the expression of CD44, and implanted different numbers of cells
in the right striatum of NOD-SCID mice. Tumor progression was
monitored by MRI. Cells expressing high levels of CD44 were
much more tumorigenic than the CD44low-expressing cells.
Only one out of seven mice inoculated with 100,000 CD44low
GBM1 neurosphere cells developed tumors, whereas nine outCanof nine mice generated tumors when they were inoculated with
the same number of CD44high cells (Figures 5C and 5D). More-
over, mice inoculated with 10,000 or 1000 CD44high cells gener-
ated tumors, whereas those inoculated with the same number of
CD44low cells never generated tumors. A similar result was ob-
tained with cells from two other patients (Figure 5D). Tumors
generated by the CD44high compartment reproduced the histo-
pathological characteristics of the tumor of the patient, including
the same cellular heterogeneity (Figure 5E). For example, tumors
generated in the mouse contained the same percentage (70%)cer Cell 18, 655–668, December 14, 2010 ª2010 Elsevier Inc. 659
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Figure 4. Patient-Derived Neurospheres Have a CD44high/Id1high Cell Population
(A) Cells fromGBM1 neurospheres were dissociated and seeded on coverslips. Immunocytochemistry for Id1and CD44was performed and nuclei were counter-
stained with Hoechst. Scale bar, 10 mm. Quantification of Id1 and CD44 expression levels per cell is shown.
(B) FACS analysis of CD44 levels was performed in GBM neurospheres (upper panel). Isotype control is shown. Cells with high or low levels of CD44 from the
indicated GBM neurospheres were sorted by FACS and CD44, ID1, ID2, and ID3 transcript levels were determined by qRT-PCR (lower panels). *p < 0.01;
**p < 0.001 compared to CD44low. Data are presented as means ± SD.
(C) Cells from GBM1 neurospheres were sorted by FACS according to CD44 levels, and the levels of Id1, Id3, and tubulin were determined by immunoblotting.
See also Figure S4.
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our results indicate that the CD44high compartment is enriched
for GICs, as has been shown in other tumor types.
Remarkably, neurospheres from three patients treated with
TGF-b for 7 days increased the CD44high compartment, while
neurospheres treated with the TbRI inhibitor for the same
time decreased the CD44high compartment (Figure 5F). A time-
course of TGF-b treatment showed that CD44 began to be
induced by TGF-b after 24 hr of treatment, and peaked at
7 days (Figure S5B). Moreover, inhibition of protein translation
through the treatment with cycloheximide prevented the induc-
tion of CD44 by TGF-b, indicating that this phenomenon
requires protein synthesis (Figure S5C). Thus, the regulation
of CD44 by TGF-b was slow and indirect, suggesting that
TGF-b induced CD44 as a result of a transdifferentiation
process.660 Cancer Cell 18, 655–668, December 14, 2010 ª2010 Elsevier IncAltogether, our results demonstrate that TGF-b regulates the
CD44high compartment, which expresses high levels of Id1 and
is enriched for GICs.
The Effect of the TbRI Inhibitor on the CD44high Cell
Population and the Tumor-Initiating Capacity of GICs
Is Mediated by the Decrease of Id1 and Id3 Expression
Next, we assessed whether the regulation of Id1 and Id3 levels
by TGF-bmediated the effect of TGF-b on the CD44high popula-
tion and, hence, on the tumor-initiating capacity of neuro-
spheres. We specifically decreased the levels of Id1 and Id3 by
RNA interference (Figure 6A; Figure S6A). Knockdown of Id1 or
Id3 separately did not have a major effect (Figure S6B), while
cells expressing low levels of Id1 and Id3 had a reduced self-
renewal capacity after serial plating (Figure S6C). This indicated
functional redundancy between Id1 and Id3. Control and Id1 and.
Cancer Cell
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TbRI inhibitor, and the CD44high population was determined.
Neurospheres expressing lower levels of Id1 and Id3 had
a decreased amount of CD44high cells than control cells (Figures
6A and 6B). Interestingly, the CD44high population in cells
expressing shRNAs targeting Id1 and Id3 was similar to that in
TbRI inhibitor-treated cells (Figure 6B). Moreover, the treatment
of the Id-knockdown cells with the TbRI inhibitor did not signifi-
cantly decrease the CD44high population, showing that the effect
of the TbRI inhibitor is in large part mediated by the decrease of
Id1 and Id3 (Figure 6B).
We also overexpressed Id1 to a level similar to that achieved
with the treatment with TGF-b (Figure 6A). The levels of Id1 over-
expression were not affected by the treatment with the TbRI
inhibitor (Figure 6A). Cells overexpressing Id1 presented an
increased CD44high population that was not regulated by the
TbRI inhibitor (Figure 6B). In addition, the effect of the TbRI inhib-
itor on neurosphere self-renewal was blunted by the overexpres-
sion of Id1 (Figure S6D).
We then determined whether the levels of Id1 and Id3 proteins
could affect the tumor-initiating capacity of the GBM neuro-
spheres. Cells from the neurospheres infected with control lenti-
virus and lentivirus expressing shRNAs targeting Id1 and Id3
were inoculated in the brain of NOD-SCID mice. Tumor progres-
sion was monitored by MRI. Cells that expressed shRNAs
against Id1 and Id3 generated smaller tumors, and with lower
incidence than control cells (Figures 6C–6E). In addition, control
neurospheres were pretreated in vitro with the TbRI inhibitor for
7 days, then dissociated and inoculated inmice. Cells pretreated
with the TbRI inhibitor generated fewer and smaller tumors, simi-
larly to the cells expressing Id1 and Id3 shRNAs (Figures 6C–6E).
This indicates that the knockdown of Id1 and Id3 and the treat-
ment with the TbRI inhibitor had a similar effect on GICs in
decreasing the tumorigenic capacity of the neurospheres.
To evaluate further the role of Id1 in the response to the TbRI
inhibitor, we inoculated Id1-overexpressing cells untreated or
pretreated in vitro with the TbRI inhibitor. Cells overexpressing
Id1 generated tumors earlier and with a higher incidence than
control cells (Figures 6F–6H). Moreover, treatment with the
TbRI inhibitor did not affect the tumor initiation capacity of Id1-
overexpressing cells in contrast to control cells (Figures
6F–6H). These results showed that Id1 overexpression confers
resistance to the TbRI inhibitor treatment, and proved that the
downregulation of Id1 is required to mediate the effect of the
TbRI inhibitor on GICs.
Previous work from our group and others (Ikushima et al.,
2009; Penuelas et al., 2009) has shown that TGF-b can regulate
GICs through the induction of LIF (Penuelas et al., 2009) and
Sox2 and Sox4 (Ikushima et al., 2009). Indeed, treatment of
GBM neurospheres with TGF-b increased the levels of Id1, Id3,
LIF, Sox2, and Sox4 (Figure S6E), indicating that TGF-b regulates
a gene program that controls GIC self-renewal. Interestingly, this
TGF-b gene program is interrelated, since Id1 and Id3 knock-
down decreases the basal levels and the TGF-b-induced levels
of LIF and Sox2 and Sox4, suggesting that Id1 and Id3 control
the expression of the rest of the genes of the program (Figures
S6F and S6G). In order to address how LIF, Sox2, and Sox4
regulated the CD44high/Id1high cell compartment, we knocked
down LIF, Sox2, and Sox4 independently. We observed thatCana lower level of LIF, Sox2, and Sox4 induced a decrease in the
CD44high population (Figures S6H and S6I), indicating that these
three proteins are required for the maintenance of the CD44high/
Id1high population. Hence, TGF-b induces the expression of a set
of proteins (Id1, Id3, LIF, Sox2, and Sox4) that are required to
maintain the CD44high population.
We analyzed the effect of the TbRI inhibitor on the CD44high
population compared to the CD44low population. As expected,
treatment of the CD44high compartment with the TbRI inhibitor
decreased the levels of Id1. Interestingly, some TGF-b-depen-
dent Id1 expression was present in the CD44low compartment,
since the TbRI inhibitor also downregulated the relatively low
levels of Id1 in the CD44low population (Figure S6J). We observed
that, while the TbRI inhibitor decreased cell proliferation in the
CD44high compartment (measured by BrdU incorporation and
cell counting), there was no effect of the TbRI inhibitor on the
CD44low population (Figures S6K and S6L). Moreover, when
neurospheres were induced to differentiate through treatment
with serum, the knockdown of Id1 and Id3 did not have a major
effect on cell proliferation (Figures S6M and S6N). This is in sharp
contrast to the effect of the TbRI inhibitor on GBM neurospheres
(see Figure 6), and indicates that the effect of the TbRI inhibitor
on Id1 and Id3 has a relevant and specific role in the CD44high
compartment.
In Vivo Treatment of Tumors with TbRI Inhibitors
Prevents Tumor Cells to Regenerate Tumors in Mice
In many cases, failure with cancer treatment is not due to lack of
primary response, but to tumor recurrence in which CICs are
thought to have a crucial role. If TGF-b inhibitors decrease the
GIC population in tumors, this should affect tumor relapse. To
test this hypothesis, we generated tumors in mice through the
inoculation of GBM1 neurospheres. Forty days after inoculation
of cells, mice generated tumors that were detected by MRI. At
that point, mice were treated with vehicle or the TbRI inhibitor
for 10 days, and sacrificed. Human tumor cells were isolated
from the mouse brain through sorting of human MHC-I-positive
cells (Figure 7A). Cells obtained from mice that were treated
with the TbRI inhibitor showed lower levels of ID1, ID3, and
CD44 transcripts, as measured by qRT-PCR (Figure 7B). More-
over, the percentage of CD44high cells was reduced in tumors
from TbRI inhibitor-treated mice (Figure 7C). We then evaluated
the capacity of the TbRI inhibitor-treated cells to relapse by inoc-
ulating cells isolated frommice treated or untreatedwith the TbRI
inhibitor in secondary mice. Indeed, cells obtained from TbRI
inhibitor-treated mice generated less and smaller tumors than
cells obtained from vehicle-treated mice (Figures 7A, 7D, and
7E). Hence, our results indicate that in vivo treatment of tumors
with TGF-b inhibitors decreases the ability of cells to reinitiate
tumors in another recipient mouse, suggesting that TGF-b inhib-
itors could be effective against tumor recurrence.
Combined Expression of Id1 and CD44 Is a Poor
Prognosis Factor in Human GBM, and Cells Expressing
Id1 andCD44Tend toBe Located in aPerivascular Niche
In order to analyze the presence and location of Id1-positive cells
in human GBM, we performed an immunohistochemical analysis
of Id1 in 43 cases of GBM. Id1 staining was present in endothelial
cells and in a fraction of tumor cells ranging from less than 5% tocer Cell 18, 655–668, December 14, 2010 ª2010 Elsevier Inc. 661
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Figure 5. The CD44 high Population in Neurospheres Is Enriched for GICs and Is Regulated by the TGF-b Pathway
(A) FACS analysis of CD44 levels was performed in GBM1 neurospheres cultured in the presence or absence of 10% FBS for 10 days.
(B) GBM1 neurosphere cells with high or low levels of CD44were sorted and seeded in neurospheremedium. After replating, cells were dissociated, counted, and
a neurosphere-forming assay was seeded. The number of neurospheres was determined after 7 days to determine the percentage of neurosphere-forming cells
*p < 0.05. Data are presented as means ± SD.
(C–E) Neurosphere cells with high or low levels of CD44 were sorted, and the indicated number of cells was inoculated in the brain of immunocompromisedmice
(C) Forty days after surgery, images from the entire mouse brains inoculated with 105 GBM1 cells were generated by MRI (arrowheads indicate tumors). (D) The
number of mice bearing tumors, as determined byMRI versus total inoculatedmice, is shown. (E) Immunohistochemistry of the indicated proteins and H&E stain
ing of the tumors were performed. Scale bar, 50 mm.
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Figure 6. Id Proteins Mediate the Effect of TGF-b on the CD44high Population and the Oncogenic Potential of GBM Neurospheres
(A) Cells from GBM1 were infected with the indicated lentivirus. Neurospheres were treated with 100 pM TGF-b1 for 3 hr, 2 mM TbRI inhibitor for 8 hr, or left
untreated, and the levels of Id1, Id3, p-Smad2, Smad2, and tubulin were determined by immunoblotting.
(B) Cells from GBM1 neurospheres previously infected with the indicated lentivirus were treated with 100 pM TGF-b or 2 mM TbRI inhibitor for 7 days or left
untreated. FACS analysis of CD44 levels (left panel) and quantification of the frequency of CD44high cells are shown (right panel). Bars represent the percent
of CD44high cells in untreated, TGF-b-treated, and TbRI inhibitor-treated lentiviral-infected neurospheres, as indicated. Data are presented as means.
(C–E) Cells from GBM1 neurospheres previously infected with the indicated lentivirus were treated for 7 days with 2 mM TbRI inhibitor, or left untreated. Subse-
quently, cells were dissociated, counted, and equal numbers of cells were inoculated in the brain of NOD-SCID mice. (C) Images from the entire mouse brains
were obtained byMRI. Arrowheads indicate tumors. (D) Tumor area was quantified (p = 0.004 comparing mice inoculated with untreated neurospheres with mice
inoculated with neurospheres treatedwith the TbRI inhibitor; p = 0.002 comparingmice inoculated with neurospheres infectedwith the lentivirus control withmice
inoculated with neurospheres infected with the sh2 ID1/ID3). (E) Tumor incidence was determined. Data are presented as means ± SD.
(F–H) Cells fromGBM1 neurospheres previously infected with the indicated lentivirus were treated during 7 days with 2 mMTbRI inhibitor or left untreated. Subse-
quently, cells were dissociated, counted, and equal numbers of cells were inoculated in the brain of immunocompromisedmice. (F) Images from the entire mouse
brains were obtained by MRI. Arrowheads indicate tumors. (G) Tumor area was quantified (p = 0.04 comparing mice inoculated with control neurospheres with
mice inoculated with Id1 overexpressing neurospheres), and (H) tumor incidence was determined. Data are presented as means ± SD. See also Figure S6.
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TbRI Inhibitors Target CD44high/Id1high GICs60% (Figure 8A). Interestingly, Id1 staining did not always over-
lap with CD44 staining (data not shown). However, the careful
analysis of the Id1 staining showed that, in around 20% of the
tumors, Id1-expressing cells tend to localize in the proximity of
tumor vessels (detected through CD31 staining) and coexpress
high levels of CD44 (Figures 8B and 8C). We quantified the local-(F) Cells from the indicated GBM neurospheres were left untreated or treated for 1
by FACS analysis. Right panels show quantification of the percentage of CD44hi
Canization of Id1+ cells in four different patients, and found that
around 70%–90% of the Id1+ cells were located within 100 mm
from vessels (Figure S7A). The perivascular reinforcement of
Id1 and CD44 staining indicated that the CD44high/Id1high GICs
tend to be localized in endothelial niches (Figures 8B and 8C;
Figure S7A).0 days with 100 pM TGF-b or 2 mMTbRI inhibitor. CD44 levels were determined
gh cells. Data are presented as means. See also Figure S5.
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Figure 7. TbRI Inhibitor Decreases Id1, Id3, and CD44 Levels in Tumors and Prevents Tumor Recurrence in Vivo
(A) Scheme showing the experimental procedure.
(B and C) Cells from GBM1 neurospheres were inoculated in the brain of immunocompromised mice. Forty days after surgery, mice were orally treated twice
a day with 100 mg/kg of TbRI inhibitor for 10 days. Subsequently, human tumor cells were isolated from the brain of mice treated or untreated with TbRI inhibitor
through sorting of human MHC-I-positive cells. (B) ID1, ID3, and CD44 transcripts levels were determined by qRT-PCR, and (C) CD44 levels were assessed by
FACS. Isotype control is shown. Data are presented as means ± SD.
(D and E) Human tumor cells obtained from mice treated or untreated with the TbRI inhibitor were inoculated in the brain of secondary mice. (D) Thirty days after
surgery, images from the entire mouse brains were obtained by MRI, tumor area was quantified (n = 4 mice inoculated with cells from untreated mice; n = 8 mice
inoculated with cells from TbRI inhibitor treated mice), and (E) tumor incidence was determined. Data are presented as means ± SD.
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TbRI Inhibitors Target CD44high/Id1high GICsIf CD44high/Id1high cells are enriched in GICs, patients with high
levels of this type of cells should have a worse prognosis, since
GICs are responsible for tumor resistance to therapy and tumor
relapse. To test this hypothesis, we analyzed the REMBRANDT
database and observed that patients with GBM tumors express-
ing simultaneously high levels of Id1 and high levels of CD44 had
a shorter overall survival than the rest of the patients (Figure 8D).
This indicates that the combination of high levels of Id1 and
CD44 is a poor prognosis factor in GBM, further confirming
that CD44high/Id1high cells might have a critical role in tumor
progression and relapse. Interestingly, high levels of Id1 in isola-
tion also conferred poor prognosis in patients with GBM, and,
moreover, GBM patients with high levels of Id1 and Id3 showed
a trend toward a shorter life expectancy, although it was not
statistically significant (Figures S7B and S7C).
Treatment of a GBM Patient with the TbRI Inhibitor
Decreased the Id1 and CD44 Levels in the Tumor
A phase I-II clinical trial is being conducted in our hospital to test
LY2157299, a derivative of the TbRI inhibitor that we used in this
study (Calvo-Aller et al., 2008). A salvage surgical resection was
indicated for one patient after 2 months on treatment. Since we
already had a sample of the same patient’s tumor prior to being
enrolled in the TbRI inhibitor study, we were able to compare664 Cancer Cell 18, 655–668, December 14, 2010 ª2010 Elsevier Incsamples before and after treatment with the TbRI inhibitor. Due
to the heterogeneity of GBM tumors, randomly selected areas
of the same tumor mass were analyzed. Levels of Id1 and
CD44 were determined in samples from the tumor prior to
and after treatment with the TbRI inhibitor. The levels of Id1
and CD44 were decreased in the samples obtained after
treatment with the TbRI inhibitor (Figures S7D and S7E), confirm-
ing our results that the TbRI inhibitor targets the CD44high/Id1high
cell population in the context of just one human patient.
DISCUSSION
The hypothesis that, within the heterogeneous tumor mass, cells
with characteristics of stem cells are responsible for tumor initi-
ation, recurrence, and resistance to therapy is redirecting the
therapeutic efforts against cancer (Dick, 2008; Gupta et al.,
2009a; Zhou et al., 2009). CICs should be targeted in order to
eradicate tumors and, hence, the understanding of themolecular
pathways involved in the control of CICs will provide effective
therapeutic targets against cancer. With this in mind, we decided
to address the mechanisms of action of the TGF-b inhibition
in GBM.
The TGF-b pathway has a relevant role in cancer, and several
anti-TGF-b compounds are now under clinical development. In.
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Figure 8. Id1 and CD44 Coexpression Correlates with Overall Survival in GBM Patients
(A) A tissue microarray of 43 different GBM patients was stained with an antibody against Id1 and the frequency of Id1-positive nuclei was calculated.
(B) CD44/Id1 and CD31/Id3 double immunofluorescence of samples from GBM patients. Magnification of the indicated areas stained with Id1/CD44 and Id3/
CD31 are shown in the right panels. Nuclei were counterstained with Hoechst. Scale bar, 50 mm.
(C) CD44, Id1, and CD31 immunohistochemistry of samples from GBM patients. Scale bar, 100 mm.
(D)Kaplan-Meier curves showing that the overall survival of patientswith both ID1mRNA levels upregulatedR3-fold andCD44mRNA levels upregulatedR10-fold
is significantly lower than the rest of the patients (p = 0.03) by log-rank test. Data obtained from the Repository for Molecular Brain Neoplasia Data (REMBRANDT)
program form the National Cancer Institute. See also Figure S7.
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TbRI Inhibitors Target CD44high/Id1high GICsglioma, TGF-b can act as an oncogenic factor, and is considered
a therapeutic target. Indeed, here we used a model of GBM
based on the inoculation of patient-derived GICs in NOD-SCID
mice reproducing the original tumor from the patient. Using
this preclinical model, we observed that treatment with TGF-b
inhibitors prevented GBM growth. In order to study the effect
of TGF-b inhibitors on GBM, we decided to pursue an unbiased
approach to identify all the common gene responses to the TbRI
inhibitor in patient-derived tumor cells. ID1 and ID3were present
among the genes regulated by the TbRI inhibitor. Id proteins
have been shown to be involved in cell differentiation (Perk
et al., 2005), and, recently, Id1 has been described to be highly
expressed in neural stem cells (Nam and Benezra, 2009). For
this reason, we hypothesized that the TbRI inhibitor could have
an effect on GICs through the regulation of Id1 and Id3 proteins.
Indeed, Id1 and Id3 are expressed in patient-derived neuro-
spheres, and treatment of neurospheres with the TbRI inhibitor
decreased Id1 and Id3 expression.
In GBM neurospheres, TGF-b induces ID1 transcription
through a TGF-b-responsive element located at the same
promoter region previously described to support the repression
of ID1 transcription by TGF-b in epithelial cells (Kang et al., 2003).CanThus, TGF-b promotes two transcriptional opposed responses in
epithelial cells and GBM neurospheres through the same
promoter region. This antagonistic context-dependent response
to TGF-b depends on the activity of the TNF-a pathway. TNF-a
induces the transcriptional repressor ATF3 that, in epithelial
cells, is recruited to the Id1 promoter by an activated Smad
complex (Kang et al., 2003). In GBM neurospheres, in contrast
to epithelial cells, ATF3 is not expressed, and the Smad complex
acts as a transcriptional activator of the Id1 promoter. When
GBM neurospheres are treated with TNF-a, TGF-b loses the
ability to induce Id1. Hence, the dual response of Id1 to TGF-b
is controlled by the crosstalk of TGF-b and TNF-a through,
most likely, ATF3.
We observed that the expression of Id1 in patient-derived neu-
rospheres was heterogeneous, with some cells expressing high
levels of nuclear Id1. Interestingly, cells expressing high levels of
Id1 coexpressed high levels of CD44. Several reports have
shown that CICs of different tumor types (i.e., breast, colon,
and prostate) are characterized by the expression of high levels
of CD44 (Visvader and Lindeman, 2008). However, in glioma,
CD44 has not been described as a marker to identify GICs. We
observed that the CD44high/Id1high population was enriched forcer Cell 18, 655–668, December 14, 2010 ª2010 Elsevier Inc. 665
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TbRI Inhibitors Target CD44high/Id1high GICsGICs and generated tumors reproducing the heterogeneous cell
population of the original tumor from the patient. Of note, Id1 has
recently been shown to be expressed in the B1 type adult neural
stem cells (Nam and Benezra, 2009), suggesting a parallelism
between GICs and normal neural stem cells. Remarkably,
TGF-b regulated the CD44high/Id1high population. The effect of
TGF-b and the TbRI inhibitor on the CD44high/Id1high compart-
ment took several days, and was dependent on protein
synthesis, indicating that TGF-b controlled the cell differentiation
status of the CD44high/Id1high population through, most likely,
epigenetic regulation.
Taking into account that TGF-b regulated Id1 and CD44
expression, and that the Id1 regulation was prior to CD44, we
hypothesized a causal relationship between the two effects.
Indeed, Id1 and Id3 knockdown and Id1 overexpression
decreased and increased, respectively, the CD44 high cell popu-
lation. In addition, Id1 overexpression blunted the effect of the
TbRI inhibitor on the CD44high compartment. Thus, TGF-b and
the TbRI inhibitor regulate the CD44high/Id1high GIC population
in tumors through the regulation of Id1 and Id3, and, moreover,
the decrease of Id1 is required for the effect of the TbRI inhibitor
on GICs.
Our previous work and that of others (Ikushima et al., 2009;
Penuelas et al., 2009) has shown that TGF-b is involved in the
control of GICs through the induction of LIF, Sox2, and Sox4.
Our data show that LIF, Sox2, Sox4, Id1, and Id3 are elements
of a TGF-b gene program that controls and is required for the
maintenance of the CD44high/Id1high cell population. Interest-
ingly, Id1 and Id3 control the expression of LIF and Sox2 and
Sox4, indicating that Id1 and Id3 could be the master regulators
of the TGF-b-GIC gene program.
In many cases, the lack of success with GBM treatment is due
to GIC-dependent tumor relapse. In order to assess the effect of
TbRI inhibitors in GBM recurrence, we treated mice bearing
patient-derived tumors with the anti-TGF-b compound, and
determined how the treatment was affecting the CD44high/Id1high
compartment and the capacity of tumor cells to reinitiate a tumor
in another mouse recipient. In this way, we evaluated the ability
of tumor cells to relapse after treatment with the TbRI inhibitor.
Remarkably, cells isolated from tumors treated with the TbRI
inhibitor presented a decreased CD44high/Id1high compartment,
and generated less and smaller tumors than cells isolated from
tumors treated with vehicle, indicating that anti-TGF-b treat-
ments could be effective in preventing tumor recurrence through
the elimination of GICs.
TGF-b has been previously shown to be involved in CD44high
CICs. The TGF-b-mediated induction of an EMT in neoplastic
mammary epithelial cell populations has been described to
result in the enrichment of a CD44 high/CD24low population
(Gupta et al., 2009b; Mani et al., 2008). The parallelism in the
regulation of CICs observed in GBM and breast cancer is
a concept to be studied further in order to assess whether similar
mechanisms are involved in both tumor types.
In human GBM tumors, the frequency of tumoral Id1-positive
cells is diverse. Notably, a perivascular reinforcement of CD44
and Id1 staining was observed in a subgroup of tumors,
indicating that the CD44high/Id1high GICs are present in an
endothelial niche, as has been described previously for CICs.
Since GICs are responsible for tumor initiation, propagation,666 Cancer Cell 18, 655–668, December 14, 2010 ª2010 Elsevier Incand resistance to therapy, tumors with a high frequency of
CD44high/Id1high cells should be associated with a poor prog-
nosis. Indeed, high Id1 and high CD44 expression in human
GBM inversely correlates with survival.
We were able to confirm our results in the context of one
human patient treated with the TbRI inhibitor. Since a phase I-II
trial is being conducted in our hospital, we were able to obtain
tumor specimens from the same patient before and after treat-
ment with the TbRI inhibitor. Treatment with the TbRI inhibitor
repressed the expression of Id1 and CD44 in the tumor of the
patient, confirming that the inhibition of the TGF-b pathway
targets the CD44high/Id1high cell population.
The characteristics that define GICs make these cells the crit-
ical therapeutic target against cancer, and treatments that do not
target GICs will eventually result in tumor relapse. Our work
shows that the TGF-b-Id1-CD44 axis regulates GICs, and that
anti-TGF-b compounds could decrease the GIC population by
inducing the transdifferentiation of the CD44high/Id1high popula-
tion into a CD44low/Id1low population. Interestingly, several ther-
apeutic anti-TGF-b compounds are now being tested in clinical
trials (Seoane, 2008). Our results suggest that those compounds
could be effective against GICs and GBM, providing hope in this
dismal disease.
EXPERIMENTAL PROCEDURES
Cell Lines and Primary Cell Cultures
PCTCs and GBM neurospheres were generated as described previously
(Bruna et al., 2007; Gu¨nther et al., 2008). Briefly, tumor samples were pro-
cessed within 30 min after surgical resection. Minced pieces of human GBM
samples were digested with 200 U/ml collagenase I (Sigma) and 500 U/ml
DNase I (Sigma) in PBS for 2 hr at 37C with constant vigorous agitation.
The single-cell suspension was filtered through a 70 mm cell strainer (BD
Falcon) and washed with PBS. Finally, cells were resuspended and subse-
quently cultured in DMEM with 10% FBS (for PCTC culture) or in neurosphere
medium (for GBM neurospheres). The neurosphere medium consisted of Neu-
robasal medium (GIBCO) supplemented with B27 (GIBCO), L-glutamine
(GIBCO), penicillin/streptomycin, and growth factors (20 ng/ml EGF and
20 ng/ml FGF-2; PeproTech). Human GBM specimens were obtained from
the Vall d’Hebron Hospital. The clinical protocol was approved by the Vall
d’Hebron institutional review board, with informed consent obtained from all
subjects.
Plasmids and Reagents
TGF-b1 (R&D Systems), TNF-a (Roche), TbRI inhibitor LY2109761 (Eli Lilly),
SB431542 (Tocris), and cycloheximide (Sigma) were used at the indicated
concentrations. Specific antibodies against p-Smad2, Smad2 (Cell Signaling),
a-Tubulin (Sigma), Id1 (C20; Santa Cruz Biotechnology), Id3 (Biocheck), and
lamin A/C and ATF3 (Santa Cruz Biotechnology) were used for immunoblot-
ting. Antibodies against IgG (Upstate) and Smad4 (Hata et al., 2000) were
used for ChIP. The following antibodies were used for the detection of proteins:
anti-Id1 and anti-Id3 (both from BioCheck); anti-CD44 (Ab-4; Neomarkers);
anti-CD31 (clone JC70A [DAKO] and clone 1A10 [Invitrogen]); and anti-
SSEA-1 (clone MMA; Abcam).
Where indicated, a nuclear protein extraction was performed using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Pierce), according to the
manufacturer’s recommendations.
Lentiviral constructs expressing Id1 (cDNA kindly provided by Dr. Francesc
Ventura) or short hairpins targeting ID1, ID3,LIF,SOX2, andSOX4 (OpenBiosys-
tems, Thermo Scientific) were produced and packaged as previously described
(Zufferey et al., 1997). Neurospheres were dissociated in growth media, mixed
with virus, and plated. Polybrene (Sigma) was added at a concentration
of 8 mg/ml. Cells were incubatedwith virus for 12 hr,washedwith PBS, and incu-
bated in fresh media as previously described (Zufferey et al., 1997)..
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For the neurosphere-forming essay, equal numbers of cells were seeded at
low cell density (4 cells/ml) in wells of a 96 well plate. Cells were treated with
the indicated compounds, and the total number of newly formed neurospheres
was counted after 7 days in culture.
For the self-renewal assay, neurospheres were treated with the indicated
compoundsduring 7days, and then cellswere dissociated, counted, and equal
numbers of cells were replated at low cell density (4 cells/ml) without treatment
in wells of a 96 well plate. The total number of newly formed neurospheres was
counted after 7 days in culture, and the percentage of neurosphere-forming
cells was determined (Lee et al., 2008; Reynolds and Weiss, 1996).Intracranial Tumor Assay
All mouse experiments were approved by and performed according to the
guidelines of the institutional animal care committee of the Vall d’Hebron
Research Institute in agreement with the European Union and national direc-
tives. The cells were stereotactically inoculated into the corpus striatum of the
right brain hemisphere (1 mm anterior and 1.8 mm lateral to the bregma;
2.5 mm intraparenchymal) of 9 week-old NOD-SCID mice (Charles River Labo-
ratories). Micewere euthanizedwhen they presented neurological symptoms or
a significant loss of weight. MRI analysis was performed in mice injected intra-
peritoneally with gadolinium diethylenetriamine penta-acetic acid at a dose of
0.25 mmol gadolinium/kg body weight. T1W MRI images were acquired in
a 9.4 T vertical bore magnet interfaced to an AVANCE 400 system (Bruker)
with a spin-echo sequence, as described previously (Penuelas et al., 2009).Analysis of the CD44-Positive Population by Flow Cytometry
Neurospheres were dissociated and individual cells were incubated for 15 min
in blocking solution containing 10 mg/ml human IgG, followed by anti-CD44
antibody or the control IgG2b isotype, both FITC conjugated (BD Pharmingen).
Cells were incubated for 20 min on ice protected from light, washed in PBS,
and stained with propidium iodide (Sigma) to discriminate dying cells. Cells
were then analyzed by flow cytometry (FACSCalibur; Beckton Dickinson) or
sorted (MoFlo; DAKO) after staining with CD44-FITC.Isolation of Human Cells from Orthotopic Xenografts in Mouse
Brains
Brains from mice inoculated with neurospheres were dissociated and stained
with the pan-MHC-I-specific monoclonal antibody (mAb) HP-1F7 (Santa Cruz
Biotechnology), followed by secondary PE-conjugated mAb (Dako Cytoma-
tion) for subsequent cell sorting of human MHC-I-positive cells (MoFlo-
DAKO). Cells obtained were washed and immediately used in subsequent
experiments.Microarray Expression Analysis
RNA was assayed on the Affymetrix microarray platform with the Human
Genome U133 Plus 2.0 GeneChips and analyzed with Genespring GX v7.3
(Agilent). The microarray data have been deposited in the Gene Expression
Omnibus (GEO)/NCBI public database (accession no. GSE23935).Statistical Analysis
Student’s t test and ANOVA were performed for statistical analysis. Data in
graphs are presented as means ± SD.ACCESSION NUMBERS
Coordinates have been deposited in the Gene Expression Omnibus (GEO)/
NCBI public database with accession code GSE23935.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at doi:10.1016/j.
ccr.2010.10.023.CanACKNOWLEDGMENTS
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